Literature DB >> 15707589

Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis.

Chang Xiao1, Bao Feng Yang, Jin H Song, Howard Schulman, Liang Li, Chunhai Hao.   

Abstract

TRAIL can induce apoptosis in melanoma cells and thus may offer new hope for melanoma therapy. However, many melanoma cells are resistant to TRAIL. To examine molecular mechanisms in cell resistance, we analyzed TRAIL-induced DISC in TRAIL-sensitive melanoma cells and showed that apoptosis-initiating caspase-8 and caspase-10 were recruited to the DISC where they became activated through autocatalytical cleavage, leading to apoptosis through cleavage of downstream substrates such as caspase-3 and DFF45. In TRAIL-resistant melanoma cells, however, c-FLIP proteins were recruited to the DISC, resulting in the inhibition of caspase-8 and caspase-10 cleavage in the DISC. Both calmodulin-dependent protein kinase II (CaMKII) protein and enzymatic activity were upregulated in resistant cells and CaMKII inhibitor KN-93 downregulated expression of c-FLIP proteins, thus sensitizing resistant cells to TRAIL-induced apoptosis. Transfection of CaMKII cDNA in sensitive melanoma cells resulted in cell resistance to TRAIL, where transfection of CaMKII dominant-negative cDNA in resistant cells restored TRAIL sensitivity in cells. These results indicate that the CaMKII-mediated pathway for c-FLIP upregulation protects melanoma cells from TRAIL-induced apoptosis and targeting this pathway may provide novel therapeutic strategies in treatment of melanomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15707589     DOI: 10.1016/j.yexcr.2004.11.002

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  25 in total

1.  mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Authors:  Amith Panner; Jean L Nakamura; Andrew T Parsa; Pablo Rodriguez-Viciana; Mitchel S Berger; David Stokoe; Russell O Pieper
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

2.  Memory Erasure Experiments Indicate a Critical Role of CaMKII in Memory Storage.

Authors:  Tom Rossetti; Somdeb Banerjee; Chris Kim; Megan Leubner; Casey Lamar; Pooja Gupta; Bomsol Lee; Rachael Neve; John Lisman
Journal:  Neuron       Date:  2017-09-27       Impact factor: 17.173

3.  Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.

Authors:  Mary M McCarthy; Kyle A DiVito; Mario Sznol; Daniela Kovacs; Ruth Halaban; Aaron J Berger; Keith T Flaherty; Robert L Camp; Rossitza Lazova; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

Review 5.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

6.  Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

Authors:  Alena Vaculova; Vitaliy Kaminskyy; Elham Jalalvand; Olga Surova; Boris Zhivotovsky
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

Review 7.  c-FLIP, a master anti-apoptotic regulator.

Authors:  A R Safa
Journal:  Exp Oncol       Date:  2012-10

Review 8.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

9.  Persistent reversal of enhanced amphetamine intake by transient CaMKII inhibition.

Authors:  Jessica A Loweth; Dongdong Li; James J Cortright; Georgia Wilke; Okunola Jeyifous; Rachael L Neve; K Ulrich Bayer; Paul Vezina
Journal:  J Neurosci       Date:  2013-01-23       Impact factor: 6.167

10.  Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.

Authors:  David S Hill; Shaun Martin; Jane L Armstrong; Ross Flockhart; Joge J Tonison; Dominic G Simpson; Mark A Birch-Machin; Christopher P F Redfern; Penny E Lovat
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.